Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC 007 in Chronic Heart Failure with Autoantibodies
NCT04192214Phase 2Completed
- Sponsor
- Berlin Cures
- Start
- Mar 2019
- Primary completion
- Dec 2022
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rovunaptabin in chronic heart failure (CHF) and dilated cardiomyopathy (DCM) (2 arms), sponsored by Berlin Cures. Primary endpoint: Proportion of β1 AAb negative participants at month 12. Started Mar 2019; status: completed.
02
Drugs
rovunaptabin
03
Conditions
chronic heart failure (CHF)dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT04192214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192214.